Subjects was Grouped for Clinical Test on the Quadrivalent Meningococcal Conjugate Vaccine (MCV4) — Another Key Product of AIM Vaccine

2023-03-17 Source:Aimbio
Another key product — quadrivalent meningococcal conjugate vaccine (MCV4) has been developed independently by AIM Vaccine. On March 15, the clinical test was officially carried out at Yanshan Disease Prevention and Control Center in Yunnan Province and related subjects were grouped.

This product is one of the global top 10 vaccines. It employs polysaccharide protein chemical coupling technology to bind four common pathogenic meningococcus polysaccharides, i.e. A, C, W135, and Y to carrier protein CRM197 via covalent bonds respectively, which can induce children below 2 years old to produce immune response and thus provide protection for this group of people.

The quadrivalent meningococcal conjugate vaccine (MCV4) is a world-class innovative vaccine recognized by the industry, which can prevent epidemic cerebrospinal meningitis caused by Group A, Group C, Group Y, and Group W135 meningococcus, as well as other invasive diseases. According to the statistics of China Insights Consultancy, the market share of MCV4 in China will be more than RMB 4 billion by 2030.

ACYW 123 meningococcal polysaccharide vaccine (MPSV4), a commercialized product of AIM Vaccine, adopts mature polysaccharide purification technology. Several key technical indicators, including acetoxy group, phosphorus content, distribution of molecular sizes, and bacterial endotoxin, are better than the standard specified in Chinese Pharmacopoeia, European Pharmacopoeia and WHO Regulations. The polysaccharide used in MCV4 has been prepared by using such technology and the product continues to meet the high standard.